Compare abrdn Income Credit Strategies Fund (ACP) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Neurocrine Biosciences Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.23 (market cap $656.21M), while Neurocrine Biosciences Inc trades at $179.5 (market cap $17.84B). The key difference: Neurocrine Biosciences Inc is far larger — about 27.2× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 17.78% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| ACP | NBIX | |
|---|---|---|
Market Cap | $656.21M | $17.84B |
Sector | Financials | Health |
52-Week High | $5.98 | $177.49 |
52-Week Low | $5.01 | $123.10 |
Dividend Yield | 17.78% | — |
Enterprise Value | — | $16.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
Neurocrine Biosciences (NBIX) trades at $174.1, showing modest daily movement with a slight decline of 0.09%. The stock exhibits strong bullish technical signals from moving averages and a consensus analyst buy rating of 86.49%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.94 surpassing the $1.22 estimate. Revenue growth is robust, climbing from $2.86B in 2025 to a projected $3.1B in 2026, supported by blockbuster products Ingrezza and Crenessity.
NBIX presents a favorable outlook with upward earnings momentum and strategic acquisitions strengthening its neuroscience portfolio. Key risks include pipeline execution challenges and competitive pressures. The consensus price target of $192.91 suggests approximately 11% upside potential from current levels, making it an attractive growth stock despite elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
